Biological Effects of Dietary Restriction on Alzheimer's Disease: Experimental and Clinical Investigations DOI Creative Commons

Zijiao Liu,

Jun Zhang, Jiang Fei

et al.

CNS Neuroscience & Therapeutics, Journal Year: 2025, Volume and Issue: 31(4)

Published: April 1, 2025

ABSTRACT Backgrounds Dementia can impose a heavy economic burden on both society and families. Alzheimer's disease (AD), the most prevalent form of dementia, is complex neurodegenerative characterized by abnormal deposition extracellular amyloid β‐protein (Aβ) aggregation intracellular Tau protein to neurofibrillary tangles (NFTs). Given limited efficacy pharmacological treatment, scientists have already paid more attention non‐pharmacological strategies, including dietary restriction (DR). DR refers nutritional paradigm aimed at promoting overall health modifying balance between energy consumption expenditure. Studies demonstrated that effectively extends healthy lifespan, delays aging process, achieves promising results in prevention treatment AD preclinical studies. Methods In this review we collected related studies viewpoints searching PubMed database using keywords. Most citations were published 2015 2025. A few older literatures also included due their relevance significance field. Results We first provide concise overview current therapeutic preventive strategies for AD. Then, introduce several specific protocols favorable effects Furthermore, potential mechanisms underlying benefits are discussed. Finally, briefly highlight role maintaining brain health. Conclusion This may offer valuable insights into development innovative treatment.

Language: Английский

Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions DOI Creative Commons
Jeffrey L. Cummings

Neurotherapeutics, Journal Year: 2025, Volume and Issue: unknown, P. e00570 - e00570

Published: March 1, 2025

Language: Английский

Citations

2
Perivascular brain clearance as a therapeutic target in cerebral amyloid angiopathy and Alzheimer's disease DOI Creative Commons
Orla Bonnar, Beth Eyre, Susanne J. van Veluw

et al.

Neurotherapeutics, Journal Year: 2025, Volume and Issue: unknown, P. e00535 - e00535

Published: Jan. 1, 2025

Language: Английский

Citations

1
Donanemab: Appropriate use recommendations DOI Creative Commons

G D Rabinovici,

D. J. Selkoe,

Suzanne E. Schindler

et al.

The Journal of Prevention of Alzheimer s Disease, Journal Year: 2025, Volume and Issue: unknown, P. 100150 - 100150

Published: March 1, 2025

Language: Английский

Citations

1
Aging, mitochondrial dysfunction, and cerebral microhemorrhages: a preclinical evaluation of SS-31 (elamipretide) and development of a high-throughput machine learning-driven imaging pipeline for cerebromicrovascular protection therapeutic screening DOI Creative Commons
Roland Patai, Krish Patel,

Boglarka Csik

et al.

GeroScience, Journal Year: 2025, Volume and Issue: unknown

Published: April 2, 2025

Language: Английский

Citations

1
Recent Insights on the Role of Nuclear Receptors in Alzheimer’s Disease: Mechanisms and Therapeutic Application DOI Open Access

Xiaoxiao Shan,

Dawei Li,

Huihui Yin

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(3), P. 1207 - 1207

Published: Jan. 30, 2025

Nuclear receptors (NRs) are ligand-activated transcription factors that regulate a broad array of biological processes, including inflammation, lipid metabolism, cell proliferation, and apoptosis. Among the diverse family NRs, peroxisome proliferator-activated (PPARs), estrogen receptor (ER), liver X (LXR), farnesoid (FXR), retinoid (RXR), aryl hydrocarbon (AhR) have garnered significant attention for their roles in neurodegenerative diseases, particularly Alzheimer’s disease (AD). NRs influence pathophysiology AD through mechanisms such as modulation amyloid-beta (Aβ) deposition, regulation inflammatory pathways, improvement neuronal function. However, dual role progression, where some may exacerbate while others offer therapeutic potential, presents critical challenge application treatment. This review explores functional diversity highlighting involvement AD-related processes discussing prospects NR-targeting strategies. Furthermore, key challenges, necessity precise identification beneficial detailed structural analysis molecular dynamics simulations, further investigation NR AD, tau pathology autophagy, also discussed. Collectively, continued research is essential to clarify ultimately facilitating potential use diagnosis, prevention, treatment AD.

Language: Английский

Citations

0
Anti‐amyloid treatments: Why we think they are worth it DOI Creative Commons
Suzanne E. Schindler, Erik S. Musiek, John C. Morris

et al.

Alzheimer s & Dementia Translational Research & Clinical Interventions, Journal Year: 2025, Volume and Issue: 11(1)

Published: Jan. 1, 2025

Abstract Years of experience watching our patients progressively decline and die from complications Alzheimer's disease (AD) has strongly motivated us to provide newly approved anti‐amyloid treatments appropriate patients. Following detailed personalized discussions the potential risks benefits these with their families, almost 300 at clinic have chosen receive lecanemab infusions. We found frequency severity complications, including amyloid‐related imaging abnormalities (ARIA), be manageable as expected based on clinical trials. While longer‐term are not yet clear, families accepting even a modest slowing progression. experienced complexities, burdens, costs, major logistical challenges associated treatment AD treatments. However, we also understand that for some current early symptomatic AD, best option fighting this devastating disease, find it worthwhile Highlights Many former died AD. Our now nearly receiving manageable. Despite challenges, worthwhile.

Language: Английский

Citations

0
Clinical and Neuroradiological Manifestations of Cerebral Amyloid Angiopathy: A Closer Look into the Natural History of a Frequent Disease DOI Open Access
Marialuisa Zedde, Fabrizio Piazza, Rosario Pascarella

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(5), P. 1697 - 1697

Published: March 3, 2025

Cerebral amyloid angiopathy (CAA) is one of the most prevalent small vessel diseases (SVDs). Its neuroradiological hallmarks are both hemorrhagic and non-hemorrhagic ones. Among clinical manifestations, transient focal neurological episodes (TFNEs) associated with an increased risk bleeding in a short time period convexal subarachnoid hemorrhage (SAH). The natural history CAA incompletely characterized literature, because focus has been mostly on events, while presentations possible sometimes underestimated. Furthermore, new diagnostic criteria have incorporated Magnetic Resonance Imaging (MRI) markers presentations. Disease trajectories often individual help provide food for thought discussion some issues, thus allowing greater deeper evaluation. We, therefore, present case that exemplifies how can be atypical compared to its expected course, which long not only hemorrhagic. Several CAA-related inflammation, prevalent, but exclusive, leptomeningeal involvement, were evaluated treated presented case, intraparenchymal cerebral manifestation was last patient’s history. may very During disease’s inflammatory features might prominent neuroimaging strongly symptomatic, (ICH) late event. awareness this subtype disease allows us better explore pathophysiology increase level suspicion diagnosis. distinction between different phenotypes useful information patient management practice.

Language: Английский

Citations

0
An update on emerging anti-amyloid-β monoclonal antibodies for treating Alzheimer’s disease: the role of apolipoprotein E DOI Creative Commons
Madia Lozupone, Vittorio Dibello,

Antonio Daniele

et al.

Expert Opinion on Emerging Drugs, Journal Year: 2025, Volume and Issue: unknown

Published: March 21, 2025

Keywords: Alzheimer's diseaseapolipoprotein Eamyloid-βARIAcerebrospinal fluidmild cognitive impairment

Language: Английский

Citations

0
Biological Effects of Dietary Restriction on Alzheimer's Disease: Experimental and Clinical Investigations DOI Creative Commons

Zijiao Liu,

Jun Zhang, Jiang Fei

et al.

CNS Neuroscience & Therapeutics, Journal Year: 2025, Volume and Issue: 31(4)

Published: April 1, 2025

ABSTRACT Backgrounds Dementia can impose a heavy economic burden on both society and families. Alzheimer's disease (AD), the most prevalent form of dementia, is complex neurodegenerative characterized by abnormal deposition extracellular amyloid β‐protein (Aβ) aggregation intracellular Tau protein to neurofibrillary tangles (NFTs). Given limited efficacy pharmacological treatment, scientists have already paid more attention non‐pharmacological strategies, including dietary restriction (DR). DR refers nutritional paradigm aimed at promoting overall health modifying balance between energy consumption expenditure. Studies demonstrated that effectively extends healthy lifespan, delays aging process, achieves promising results in prevention treatment AD preclinical studies. Methods In this review we collected related studies viewpoints searching PubMed database using keywords. Most citations were published 2015 2025. A few older literatures also included due their relevance significance field. Results We first provide concise overview current therapeutic preventive strategies for AD. Then, introduce several specific protocols favorable effects Furthermore, potential mechanisms underlying benefits are discussed. Finally, briefly highlight role maintaining brain health. Conclusion This may offer valuable insights into development innovative treatment.

Language: Английский

Citations

0